HR and breast cancer: The PLATO study (NCT03900637) is an ongoing phase 2 prospective study, using the MammaPrint © assay to guide neoadjuvant systemic treatment in stage I–IIIA, HR+/HER2− breast cancer patients inaccessible to frontline breast conservative surgery: the primary objective is a 15% increase of conversion rate to breast conservative surgery eligibility [93].